No attachments available.
A--Drug Manufacturing and Formulation Program (DMFP)
Contact and place of performance
PLUGGE, RIEKA N
Kansas City, MO
USA
Four (4) Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts with a maximum ordering value of $49,999,999.00 and an ordering period from May 4, 2026 through May 3, 2036, were awarded on May 4, 2026. Concurrently, the first task orders were issued to each awardee with an effective date of May 4, 2026 through July 3, 2026, in the firm-fixed price amount totaling $5,000.00.
The National Institutes of Health, specifically the National Institute on Drug Abuse (NIDA), has awarded four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for the Drug Manufacturing and Formulation Program (DMFP). These awards, issued on May 4, 2026, carry a collective maximum ordering value of $49,999,999.00 and an ordering period extending through May 3, 2036. Initial firm-fixed-price task orders totaling $5,000.00 were concurrently issued to each awardee for performance from May 4, 2026, through July 3, 2026.
This program is classified under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC AN11 for Health R&D Services, Health Care Services, and Basic Research. Operations for this requirement are located in Kansas City, MO, and the acquisition was conducted without a set-aside.
Solicitation number 75N95024R00077 serves as the identifier for this award notice, which was finalized and published on May 5, 2026. The contracting process was managed by Rieka N. Plugge at the National Institutes of Health. No supplemental attachments were included with the formal award announcement.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.